T. Rowe Price Investment Management
EIKN

T. Rowe Price Investment Management’s Eikon Therapeutics EIKN Stock Holding History

T. Rowe Price Investment Management’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Buy
1,595,274
+372,787
+30% +$3.81M 0.01% 541
2026
Q1 		$12.9M Buy
+1,222,487
New +$16.3M 0.01% 515

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Investment Management's EIKN Position: Q2 2026 in Review

T. Rowe Price Investment Management increased its Eikon Therapeutics (EIKN) stake by 30% in Q2 2026, buying an estimated $3.81M and bringing the position to 1,595,274 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #541.

T. Rowe Price Investment Management first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • T. Rowe Price Investment Management held 1,595,274 shares of Eikon Therapeutics worth $20.8M as of Q2 2026.
  • T. Rowe Price Investment Management bought 372,787 Eikon Therapeutics shares in Q2 2026, an estimated $3.81M.
  • Eikon Therapeutics made up 0.01% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #541 holding.
  • T. Rowe Price Investment Management first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.